ResMed (RMD) Morgan Stanley 24th Annual Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Morgan Stanley 24th Annual Global Healthcare Conference summary
15 Sep, 2026Growth and market trends
Provided first-time guidance of 5%-7% revenue growth, with organic growth potentially reaching 6.3%-8.3% after adjusting for Astral.
Total addressable market estimated at 2.7 billion people globally, spanning sleep apnea, insomnia, restless legs syndrome, and COPD.
Device growth in the Americas is in the mid-single digits, while masks and accessories are growing in the high single digits.
Mega trends such as Big Pharma's GLP-1s and consumer tech (wearables) are driving increased patient funneling and diagnosis.
Strategic alliances and acquisitions (e.g., Oura, Ectosense, Somnoware, VirtuOx) are enhancing patient conversion and therapy adherence.
Patient pathway and engagement
Acquisitions like Ectosense (NightOwl), Somnoware, and VirtuOx streamline home sleep testing and therapy initiation.
Over 95,000 CME episodes with 55,000 unique clinicians have been conducted to educate primary care physicians.
Automated resupply technologies (Brightree, Snap, Snap Light) and the myAir app (10M+ users) drive ongoing patient engagement.
Generative AI (Project Dawn) integrated into myAir provides personalized sleep health tips and support, with 1.5M inquiries to date.
Peer-reviewed evidence shows that patient engagement, including resupply outreach, increases therapy adherence.
Financial performance and margin outlook
Majority of revenue growth is volume-driven, with price increases playing a minor role, especially during inflationary periods.
Inflationary pressures are mainly from freight/logistics and electromechanical components, particularly for older devices.
Supply chain productivity initiatives and modest price increases are expected to deliver low double-digit basis point improvements in gross margin annually through 2030.
Margin improvement will build progressively through the year as productivity and pricing measures take effect.
Latest events from ResMed
- Strong FY26 performance funds growth and returns as board and auditor leadership transition.RMD
Proxy filing - Board backs all 10 director nominees, auditor ratification, and advisory say-on-pay approval.RMD
Proxy filing - Revenue rose 7% core CC, EPS 14%, and shareholder returns topped $1.0B.RMD
Q1 2027 - Shareholders were asked to elect 10 directors, ratify KPMG, and approve executive pay.RMD
Proxy Filing - Ten director elections, KPMG ratification, and advisory votes anchor the ballot.RMD
Proxy Filing - Board backs all three proposals: elect 11 directors, ratify KPMG and approve say-on-pay.RMD
Proxy Filing - Board backs all agenda items, including 11 director nominees and two employee plan amendments.RMD
Proxy Filing - 2026 saw strong growth, strategic investments, and enhanced sustainability and governance.RMD
Stewardship presentation - FY26 saw 8% revenue growth, 16% EPS growth, and $1B returned to shareholders.RMD
Corporate presentation